Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants

(MedPage Today) — A winner emerged from a head-to-head comparison of direct oral anticoagulants (DOACs) for patients with acute venous thromboembolism, based on the COBRRA randomized trial. Safety events favored apixaban (Eliquis) over rivaroxaban…